SBI Okasan Asset Management Co.Ltd. Makes New $359,000 Investment in CG Oncology, Inc. $CGON

Posted by George Bondi on May 30th, 2026

SBI Okasan Asset Management Co.Ltd. bought a new position in shares of CG Oncology, Inc. (NASDAQ:CGON – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,000 shares of the company’s stock, valued at approximately $359,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in CG Oncology by 11.4% during the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company’s stock worth $264,933,000 after acquiring an additional 670,770 shares during the last quarter. Wellington Management Group LLP increased its stake in CG Oncology by 190.3% during the third quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock worth $222,055,000 after acquiring an additional 3,613,885 shares during the last quarter. Alliancebernstein L.P. increased its stake in CG Oncology by 15.0% during the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after acquiring an additional 281,637 shares during the last quarter. Bank of America Corp DE increased its stake in CG Oncology by 409.9% during the second quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock worth $45,156,000 after acquiring an additional 1,396,170 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in CG Oncology by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 1,511,533 shares of the company’s stock worth $62,773,000 after acquiring an additional 38,360 shares during the last quarter. Institutional investors and hedge funds own 26.56% of the company’s stock.

Analysts Set New Price Targets

CGON has been the subject of a number of research reports. Truist Financial reaffirmed a “buy” rating and issued a $82.00 price objective (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Wolfe Research initiated coverage on CG Oncology in a research note on Tuesday, May 19th. They issued a “peer perform” rating for the company. JPMorgan Chase & Co. lifted their price objective on CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wedbush lifted their price objective on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Finally, Royal Bank Of Canada lifted their price objective on CG Oncology from $79.00 to $81.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CG Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

Get Our Latest Research Report on CG Oncology

Insider Activity at CG Oncology

In other news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00. Following the sale, the director owned 15,600 shares in the company, valued at approximately $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.80% of the company’s stock.

CG Oncology Trading Up 2.6%

NASDAQ:CGON opened at $62.29 on Friday. The firm has a market cap of $5.49 billion, a PE ratio of -26.73 and a beta of 0.41. The stock has a fifty day moving average price of $66.91 and a 200 day moving average price of $55.45. CG Oncology, Inc. has a 12-month low of $23.65 and a 12-month high of $75.50.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.13). The company had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. Equities analysts forecast that CG Oncology, Inc. will post -2.89 EPS for the current year.

CG Oncology Profile

(Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.